Bullish & Foolish
Full HCWB fundamentals All 466 on the Survival Watch

HCWBHCW Biologics Inc.

Is HCW Biologics struggling financially?

Yes, by its own account. HCW Biologics told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Cries for help

  • Weak accounting controls

    Remediation Plans for Material Weakness in Internal Control over Financial Reporting We are committed to establishing and maintaining a strong internal control environment.

    Form 10-Q, filed 14 May 2026. Read it on SEC.gov

Signs of a way out

Nothing in the filings we have read names a way out.

Sector
Biotech/Pharma
Market cap
$4.0M
Source filing
10-Q 14 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 0months

    If the burn speeds up

    Empty by Jun 2026

  • 1month

    If it eases off

    Empty by Jul 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$741K

÷

Cash burned over the last 12 months

$13.4M

What HCW Biologics told the SEC

…financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the condensed financial statements are issued. As of March 31, 2026, the Company had not generated any revenue from commercial product sales of its…

HCW Biologics Inc., Form 10-Q, filed 14 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • Debt pressure is material Operating earnings cover only -13.4x the interest bill, so the interest is being met out of cash reserves rather than out of the business.
  • Cash burn is narrowing It is spending 46% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt